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Frequency of Porphyromonas 
gingivalis fimA in smokers and 
nonsmokers after periodontal therapy
Porphyromonas gingivalis is one of the most important Gram-negative 
anaerobe bacteria involved in the pathogenesis of periodontitis. P. gingivalis 
has an arsenal of specialized virulence factors that contribute to its 
pathogenicity. Among them, fimbriae play a role in the initial attachment and 
organization of biofilms. Different genotypes of fimA have been related to 
length of fimbriae and pathogenicity of the bacterium. Objectives: The aim 
of this study was to identify 5 types of fimA genotype strains in smokers and 
nonsmokers with periodontitis, before and after periodontal therapy. Material 
and Methods: Thirty-one patients with periodontitis harboring P. gingivalis 
were selected: 16 nonsmokers (NS) and 15 smokers (SM). Clinical and 
microbiological parameters were evaluated at baseline and 3 months after 
periodontal treatment, namely: plaque index, bleeding on probe, probing 
depth, gingival recession and clinical attachment level. The frequency of P. 
gingivalis and fimA genotype strains were determined by polymerase chain 
reaction. Results: Type I fimA was detected in the majority of SM and NS at 
baseline, and the frequency did not diminish after 3 months of treatment. The 
frequency of type II genotype was higher in SM than NS at baseline. After 
3 months, statistical reduction was observed only for types II and V fimA 
genotypes in SM. The highest association was found between types I and II 
at baseline for NS (37.5%) and SM (53.3%). Conclusion: The most prevalent 
P. gingivalis fimA genotypes detected in periodontal and smoker patients 
were genotypes I and II. However, the presence of fimA genotype II was 
higher in SM. Periodontal treatment was effective in controlling periodontal 
disease and reducing type II and V P. gingivalis fimA.
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Introduction
Recent advances in DNA sequencing and 
bioinformatics technologies have provided an 
overview of microbiomes associated with health and 
disease, thereby expanding the knowledge on putative 
pathogenic species. Differences between periodontitis 
and health now are detected at the level of phylum and 
genus, in addition to confirming previous association 
of specific species with periodontal disease, including 
P. gingivalis and T. denticola, which are two of the 
main species associated with the disease, strongly 
related to severe forms of periodontitis1. P. gingivalis 
has an arsenal of specialized virulence factors that 
contribute to its pathogenicity. Among them, fimbriae 
play a role in the initial attachment and organization 
of biofilms, and act as adhesins that mediate invasion 
and colonization of host epithelial cells2. P. gingivalis 
generally expresses two distinct fimbriae, called 
FimA and Mfa1, which are composed of polymerized 
FimA and Mfa1 proteins encoded by the fimA and 
mfa1 genes, respectively3. The P. gingivalis gene 
fim cluster consists of seven genes, fimX, pgmA and 
fimA-E, encoding FimX, PgmA and FimA-E proteins, 
respectively4. Six genotypes of fimA (I-V) and Ib were 
identified in P. gingivalis strains, and the genotype 
has been especially related to fimbriae length and 
pathogenicity of the bacterium4.
Previous studies have evaluated the association 
between the frequency of fimA genotypes and 
periodontal health status in adults5,6. P. gingivalis 
was detected in 36.8% of the healthy subjects and 
in 87.1% of the patients with periodontitis. Among 
the P. gingivalis-positive healthy adults, the most 
prevalent fimA was genotype I (76.1%), followed 
by genotype V (29.7%). In contrast, most patients 
with periodontitis carried fimA genotype II (66.1%), 
followed by genotype IV (28.9%)6. These findings 
indicate that there are both disease-associated and 
non-disease-associated strains of P. gingivalis, and 
their infectious traits, which influence periodontal 
health status, could be differentiated based on the 
clonal variation of fimA genes6.
Tobacco consumption is a risk factor for periodontal 
disease. Smoking is associated with higher clinical 
attachment loss and gingival recession, reduced 
bone height and density, and, consequently, with 
increased tooth loss5. The mechanism by which 
tobacco affects the periodontal tissue is related to 
toxic substances such as nicotine and cotinine, which 
has been associated with various cellular changes 
that may contribute to the onset and subsequent 
progression of periodontal disease7. Tobacco use 
promotes several adverse effects, such as reduced 
gingival blood flow8, oxidative stress and alterations 
in immunoinflammatory responses, reducing the 
functional activity of neutrophils such as chemotaxis, 
glycolytic activity and phagocytosis9; it also impairs 
wound healing10 and interferes on bacterial acquisition 
and host response to colonization in biofilms11. The 
frequency of periodontopathogens was previously 
investigated in smokers and nonsmokers. P. gingivalis 
has been detected more frequently in the periodontal 
pockets of smokers (66.7% – pocket depth of 3-5 mm) 
in comparison with nonsmokers (52.2%), and it has 
been found in high levels in sites with periodontitis12.
Scaling and root planing is the most common and 
well-recognized nonsurgical periodontal therapy for 
promoting improvement in clinical and microbiological 
parameters13. Few studies have assessed the 
longitudinal clinical and microbiological evaluation of 
smokers undergoing periodontal maintenance therapy, 
and controversial results have been found when 
comparing smokers with nonsmokers13,14. A reduction 
of 93% in P. gingivalis frequency for nonsmokers, 
compared to 88% for smokers, was observed in 
subgingival sites after periodontal treatment15. 
Considering the presence of different genotypes of P. 
gingivalis fimA, Teixeira, et al.16 (2009) suggested an 
association between the genotype fimA IV and disease 
severity in smoker-chronic periodontitis subjects. 
However, no study was found evaluating the influence 
of periodontal treatment on the frequency of different 
fimA genotypes in smokers and nonsmokers with 
periodontitis. The aim of this study was to compare the 
frequency of different genotypes of P. gingivalis fimA 
in smokers and nonsmokers with periodontitis, before 
and after 3 months of nonsurgical periodontal therapy. 
The null hypotheses are: 1) there is no difference in 
the periodontal status and frequency of P. gingivalis 
fimA genotypes between smokers and nonsmokers; 
and 2) smoking did not interfere in the response to 
periodontal treatment and levels of P. gingivalis fimA 
genotypes.
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Material and methods
Study population
Thirty-one patients (15 smokers – SM and 16 
nonsmokers – NS) with positive polymerase chain 
reaction (PCR) for P. gingivalis, from a total of 48 
patients (24 in each group), aged 27 to 70 years, were 
selected to participate in this study. All participants 
were recruited from the Department of Periodontology, 
School of Dentistry, Fluminense Federal University, 
Nova Friburgo, RJ, Brazil, for a period of 3 months, 
between 2014 and 2015. The study protocol was 
approved by the Research Ethics Committee of the 
Fluminense Federal University – Nova Friburgo, RJ 
(CAAE: 55894816.2.0000.5626), and registered in the 
clinical trials (NCT02879903). Prior to participation, 
the purpose and procedures were fully explained 
to all participants, who gave their written informed 
consent in accordance with the Helsinki Declaration. 
An initial sample size of 16 participants per group was 
chosen, considering the standard deviations from a 
previous study17, the effect size [gingival index (GI), 
a minimum detectable change of 10%], a power of 
80%, a significance level of 5%, and a loss to follow-
up rate of up to 20% of the participants. 
The following inclusion criteria were observed: 
presence of severe generalized chronic periodontitis 
in at least two teeth in different arches, including 
bleeding when probing these sites, probing depth 
(PPD) ≥5 mm, clinical attachment level (CAL) ≥5 
mm and radiographic bone loss involving >30% of 
site18. The participants were considered heavy SM if 
they smoked ten or more cigarettes a day for at least 
2 years. The smoking habit was confirmed at each 
visit, and the individuals who stopped smoking were 
excluded. Former SM were not included in the control 
group. The exclusion criteria were: patients with 
systemic diseases, diabetes or osteoporosis, pregnant 
and lactating females, use of immune suppressive 
medication, phenytoin, cyclosporine, calcium channel 
blockers or any antibiotics or nonsteroidal anti-
inflammatory drugs in the past 3 months, and any 
medical conditions requiring immunotherapy or people 
diagnosed with HIV+ or AIDS, which could interfere 
with the periodontium status19.
Clinical examination and periodontal therapy
Prior to clinical examination, a questionnaire was 
applied to collect information on the smoking habits 
of the participants (years of cigarette consumption 
and number consumed daily), initially at baseline 
and then after a 3-month follow-up examination. An 
experienced periodontist (GACGC) determined the 
clinical periodontal parameters, including plaque index 
(PI), bleeding on probing (BOP), pocket probing depth 
(PPD), gingival recession (GR), and clinical attachment 
level (CAL), using a periodontal probe PCP15 (PCP-
UNC15, Hu-Friedy, Chicago, IL, USA), at six sites per 
tooth on all the teeth, excluding third molars. The 
intraexaminer agreement of the categorical variables 
(PI, GI) using the kappa calculation, at the tooth level, 
was 0.75. Reproducibility of continuous variables (PPD, 
GR and CAL) was 0.70, as evaluated by the intraclass 
correlation coefficient (ICC). 
Quadrant scaling and root planing (SRP) were 
performed weekly at baseline on each participant 
under local anesthesia, using periodontal curettes 
(American Eagle, Gracey Access Curettes, Missoula, 
MT, USA) and ultrasonic scalers (Cavitron, Dentsply, 
York, PA, USA). The maintenance therapy included 
professional plaque control and SRP in recurrent 
periodontal pockets monthly during the 6 months of 
the study. No teeth had to be extracted during therapy. 
A different clinician (MGLA) conducted the periodontal 
treatment. The examiner (GACGC) had no access to 
previous recordings. All participants received oral 
hygiene instructions for home care procedures (tooth-
brushing technique, interdental cleaning and use of 
tongue scrapers). 
Microbiological samples
After performing the clinical measurements, the 
supragingival biofilm was removed with sterile gauze. 
Subgingival samples of each participant were taken 
from the sites with the deepest PPD (≥5 mm), using a 
sterile periodontal curette. Pooled biofilms from each 
site were separated in microtubes containing Tris-EDTA 
buffer (10 mM Tris– HCl, 0.1 mM EDTA, pH 7.5), and 
stored at -20°C to be analyzed microbiologically using 
the PCR assay.
Microbiological evaluation – PCR primers and 
amplification
DNA was extracted using a protocol originally 
described by Sardi, et al.19 (2011) and quantified 
in a spectrophotometer at 260 nm (Genesys 
10UV, Rochester, NY, USA), to obtain a standard 
concentration of 0.1 µg/mL, and then stored at −20°C 
to test subsequent PCR reactions. The detection of 
ABREU MGL, KAWAMOTO D, MAYER MPA, PASCOAL VAB, CAIAFFA KS, ZUZA EP, DUQUE C, CAMARGO GACG
J Appl Oral Sci. 2019;27:e201802054/8
P. gingivalis and fimA genotypes was performed as 
previously described6,19. Primers for the 16S rRNA 
gene were used as a positive control and P. gingivalis 
species-specific primers were used for the fimA 
genotypes6. All primers were custom-made by IDT 
(Integrated DNA Technologies, Sintese Biotecnologia, 
Belo Horizonte, MG, Brazil). PCR amplification was 
performed with a thermocycler AmpliTherm TX96 
Gradient (Axygen, Corning, NY, USA) under thermal 
conditions specific for each pair of primers. The PCR 
products were separated by electrophoresis in 2% 
agarose gels and Tris-borate-EDTA running buffer 
(8.0 pH). The molecular mass ladder (100 bp DNA 
ladder, Gibco, Grand Island, NY, USA) was included for 
running the agarose gel. The DNA was stained with 
0.1 µl of SYBR Safe/mL (Invitrogen, CA, USA) and 
visualized under UV light (Pharmacia LKB-MacroVue, 
San Gabriel, CA, USA). The images were photographed 
(ImageMaster – LISCAP, VDS, Pharmacia Biotech, 
Piscataway, NJ, USA) and analyzed. The amplification 
reaction was performed with the following cycling 
parameters: initial denaturation at 95°C for 10 min, 
PCR cycling consisting of 40 cycles, 94°C for 30 s, 58°C 
for 30 s, and 72°C for 30 s, followed by an extension 
at 72°C for 2 min. Positive and negative controls were 
included in each PCR set, and in each sample process. 
Statistical analysis
The statistical analysis was performed using SPSS 
Statistics 17.1 (IBM Inc., Chicago, IL, USA). All variables 
were tested for the normality of data (Shapiro-Wilk). 
Variables from participant’s characteristics and clinical 
analyses were compared between SM and NS using 
the Mann-Whitney test. Comparisons between the 
periods of time (baseline × 3 months) considering 
each group (SM and NS) separately were conducted 
using Wilcoxon tests. Differences were considered 
significant when p<0.05.
Results
Clinical results
There was no statistical difference between SM 
and NS regarding age, gender and race (Table 1). 
Median cigarette consumption was 20 cigarettes per 
day, and the duration (median) of the smoking habit 
was 23 years. Comparing SM and NS, at baseline, 
both groups had a similar periodontal status (Table 2). 
There was a statistically significant reduction in the 
clinical parameters for the NS group, with a decrease 
in PI (p=0.004) and BOP (p=0.011) indexes, and in 
PPD (p<0.001) and CAL (p=0.007) measurements, 
and also for the SM group, with a decrease in PPD 
(p<0.001) and CAL (p=0.007), comparing baseline 
with 3 months after periodontal treatment. SM 
exhibited a higher level of PI (50% -p<0.001) and 
CAL (5.68 mm – p=0.041) after 3 months than NS 
(PI: 9.69% and CAL: 3.51 mm).
fimA genotype results
P. gingivalis was detected in 16 NS and 15 SM, 
and distributed according to 5 genotypes of fimA P. 
gingivalis at baseline and 3 months after periodontal 
therapy, as described in Table 3. Genotype I was 
detected in the majority of SM (60%) and NS (87.5%) 
at baseline, and the frequency did not diminish after 
3 months of treatment (SM – 60% and NS – 93.8%). 
The frequency of genotypes II, III and V fimA 
was higher in SM than NS at baseline; however, a 
Variables Groups
Nonsmokers (NS) n=16 Smokers (SM) n=15
Age (years)† 49 (44.25-61.75) 47 (33-52)
Gender n (%)
Female 10 (62.5) 6 (40)
Male 6 (37.5) 9 (60)
Ethnicity n (%)
White 11 (73.3) 8 (50)
Black 4 (26.6) 8 (50)
Cigarettes per day† 0 20 (10-20)
Duration of smoking habit† 0 23 (10-32)
*Statistically significant differences between NS and SM groups for baseline (Mann Whitney test; p<0.05)
†Values expressed in medians (percentile 25-percentile 75)
Table 1- Characteristics of the participants
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Variables Groups
Nonsmokers (NS) 
n=16
Smokers (SM)
n=15
PI (%)
Baseline 46.04 (14.12-71.98) 49.24 (38-86)
3 months 9.69(5.04-25.37)* 50 (19.84-72.22)‡
BOP (%)
Baseline 29.91 (17.71-63.15) 23.07 (12.34-64.74)
3 months 13.15 (3.54-30)* 24.6 (13.49-30.2)
PD (mm)
Baseline 5.18 (5-5.29) 5.1 (5-5.31)
3 months 2.93 (2.65-3.81)* 3.8 (3-4.12)*‡
GR (mm)
Baseline 0.87 (0-2.62) 2 (1-2.66)
3 months 0.5 (0-2.66) 2 (1-2.57)
CAL (mm)
Baseline 5.9 (5-8.16) 7 (6.11-7.91)
3 months 3.51 (2.75-6.29)* 5.68 (4-6.74)*‡
*Statistically significant difference between baseline and 3 
months (Wilcoxon test; p<0.05)  
†Statistically significant differences between NS and SM groups 
at baseline (Mann Whitney test; p<0.05)  
‡Statistically significant differences between NS and SM groups 
at 3 months (Mann Whitney test; p<0.05
Table 2- Clinical evaluation of smokers versus nonsmokers at 
baseline and after 3 months of periodontal therapy. Values are 
expressed in medians (percentile 25-percentile 75)
fimA types Frequency in % (number of patients)
Nonsmokers (NS) Smokers (SM)
n=16 n=15
I 
Baseline 87.5(14) 60(9)
3 months 93.8(15) 60(9)
II 
Baseline 47.8(7)† 93.3(14) *
3 months 12.5(2) 13.3(2)
III 
Baseline 18.8(3) 40(6)
3 months 18.8(3) 33.3(5)
IV 
Baseline 0 0
3 months 0 0
V
Baseline 25(4) 40(6) *
3 months 18.8(3) 0
*Statistically significant difference between baseline and 3 
months (Wilcoxon test; p<0.05)  
†Statistically significant differences between NS and SM groups 
at baseline (Mann Whitney test; p<0.05)  
‡Statistically significant differences between NS and SM groups 
at 3 months (Mann Whitney test; p<0.05)
Table 3- Distribution of 5 fimA types of P. gingivalis at baseline 
and 3 months after periodontal therapy
*Statistically significant difference between baseline and 3 months (Wilcoxon test; p<0.05)
†Statistically significant differences between NS and SM groups for baseline (Mann Whitney test; p<0.05)
‡Statistically significant differences between NS and SM groups for 3 months (Mann Whitney test; p<0.05)
Figure 1- Frequency (%) of combinations of P. gingivalis fimA genes in smokers (SM) and nonsmokers (NS) at baseline and after 3 
months of periodontal treatment. Values express percentage of P. gingivalis harboring fimA types
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statistical difference was found only in the frequency 
of fimA genotype II for SM (93.3%) compared with 
NS – (47.8%) (p=0.017). After 3 months, statistical 
reduction was observed only for fimA genotypes II 
and V in SM (p=0.001).
The frequency of two different genotypes of fimA 
in NS and SM participants, at baseline and after 3 
months of treatment, are shown in Figure 1. The 
highest association was found between genotypes I 
and II at baseline for NS (37.5%) and SM (53.3%). 
Statistical differences were found between NS and 
SM, considering genotypes I and II and genotypes II 
and V, at baseline. The combination of genotypes I 
and V in SM was not detected after treatment, unlike 
NS. Comparing baseline with 3 months of treatment, 
there was a statistical reduction in the combination 
of fimA genotypes I and III for both groups. The 
combinations of genotypes I and V, genotypes II and 
V and genotypes III and V were not detected after 
treatment of SM participants.
Discussion
In this study, we confirmed that P. gingivalis is a 
common microorganism present in periodontal disease 
in SM and NS, corroborating other studies16,20. The 
virulence of P. gingivalis has been heavily associated 
with the presence of different types of fimbriae, 
which have been characterized as key factors in 
adhesion, invasion and colonization of this pathogen 
in the periodontal tissues2. However, the influence 
of periodontal treatment in the prevalence of fimA 
genotypes in SM compared with NS was not clear.
No difference was found among the groups of 
participants diagnosed with periodontal disease in 
relation to gender. Nevertheless, differences were 
found in literature with predominance of periodontal 
disease in males21 or females22. Considering ethnicity, 
no significant differences were found between the 
groups, contradicting a study that found a prevalence 
of periodontal disease for the black ethnic group23. In 
this study, the participants smoked an average of 20 
cigarettes per day, characterizing them as heavy SM. 
A study pointed that there was greater severity of 
periodontal disease in patients who consumed more 
than 20 cigarettes per day, with a 10% prevalence of 
insertion loss in heavy SM24. Light SM, who consumed 
fewer than 4 cigarettes/day had an alveolar bone 
loss of 3.3 mm, whereas heavy SM had a loss of 7.3 
mm, showing a direct relation between the number 
of cigarettes consumed and the rate of progression of 
periodontal disease6.
Some studies have shown that SM have higher 
prevalence and severity of periodontal disease, and 
worse results after periodontal therapy than NS7,25. In 
this study, SM and NS were matched by periodontal 
parameters (PI, BOP, PPD, GR and CAL) at the baseline, 
since no statistical difference was observed between 
the groups. Besides, instruction on oral hygiene was 
given to all patients, regardless of the group, in order 
not to bias data collection. However, higher levels of PI 
were observed after 3 months of periodontal treatment 
only for the SM group. One hypothesis is that smokers 
may be less motivated to keep a high-quality oral 
hygiene throughout the period of study26. Due to plaque 
accumulation, smokers showed a higher GI mean over 
3 months. This finding is opposite to what is found 
in literature data15,27, in which inflammatory levels 
generally are reduced in smokers by the influence of 
the vasoconstrictor effect of nicotine, regardless of 
the plaque index28. In addition, a significant reduction 
in the periodontal parameters PPD and CAL was 
detected for both groups, SM and NS, after periodontal 
treatment. However, SM showed lower reduction 
in probing depth and gain in clinical attachment in 
comparison with NS. The same was observed in other 
studies26,29,30. Trombelli and Scabbia29 (1997) found 
that SM with furcation problems exhibited a less 
favorable healing pattern after surgery, caused by the 
interference of nicotine on collagen synthesis and bone 
formation. Jansson and Hagstrom26 (2002) reported 
that SM have high risk of recurrence of periodontitis 
in the periodontal maintenance phase, and need more 
surgical intervention. In contrast, Zuabi, et al.30 (1999) 
observed a higher reduction in probing depth in SM 
(0.81+0.11 mm) compared to NS (0.5+0.08 mm), 
after conventional therapy, showing that the effect 
of supragingival plaque control and clinical signs of 
periodontitis is yet controversial when smoking habits 
are considered.
Many variations in the distribution of P. gingivalis 
fimA genotypes can be found in literature, depending 
on the population examined. However, one finding 
is recurrent in periodontal studies, namely, greater 
frequency of the fimA genotype II in patients with 
chronic periodontitis16,20,31. This determined that fimA 
genotypes I and II were the most prevalent at baseline 
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for both NS and SM groups, thus confirming the 
frequency of these types of fimbriae in patients with 
chronic periodontitis6. In agreement with our results, 
Beikler, et al.7 (2003) found that predominant fimA 
genotypes in 26 P. gingivalis isolates from Caucasian 
patients with periodontitis were types I (25.5%), II 
(38.2%) and IV (18.6%), by using PCR and restriction 
analysis. However, there was no difference in the 
association of the various fimA genotypes and disease 
severity. On the contrary, Teixeira, et al.29 (2000) found 
higher levels of genotype IV (69.6%) than II (28%), 
and the proportion of genotypes was associated with 
increasing probing depth only for genotype II.
Our study also found that genotype II was 
higher in SM compared to NS. The greater virulence 
of genotypes I and II can be attributed to their 
adhesiveness and invasiveness, which are key 
determinants for P. gingivalis virulence. FimA genotype 
I and II microorganisms are more adhesive to salivary 
proteins than other types, and their binding abilities 
are related to the sequence similarity of fimbrillin 
proteins20. This explains why genotypes I and II 
were more prevalent in this study, as well as in other 
studies31,32. High relative risk (RR) for the presence 
of genotype II, followed by genotypes I and III, was 
observed for SM compared with NS, at baseline, 
confirming the importance of these two genotypes for 
the development of periodontal disease.
Some studies have established that fimA genotype 
IV is considered an important virulence factor for the 
pathogenesis of periodontal disease6,32. However, in 
our study, there was no detection of type IV in the 
groups, disagreeing with some authors, who found not 
only genotypes I and II, but also genotype IV among 
the most frequently detected30,31. It is important to 
emphasize that genotyping was performed exclusively 
among participants with chronic periodontitis, and 
there was a variation in P. gingivalis genotypes 
regarding other types of periodontitis, a distinction 
that could change the course and evolution of the 
pathology.
In this study, we selected samples of P. gingivalis 
from our previous study33, in which the authors 
detected P. gingivalis in 50% of SM and 70.8% of 
NS, both groups with periodontal disease. The high 
frequency of P. gingivalis in patients with periodontitis 
is according with the results of Amano, et al.6 (2000), 
which detected P. gingivalis in 87.1% of patients with 
periodontitis. Type II fimA is associated with deeper 
pockets, whereas genotypes III and V seem to be 
involved in periodontitis to a lesser extent12. The results 
of this study corroborated with these findings, because 
a strong correlation was found between probing depth 
(>5 mm) and presence of type II fimA. Likewise, when 
associations between the fimbriae were tested in SM 
and NS at baseline and after 3 months, statistical 
analysis revealed significant differences between 
SM and NS, when II and V fimA genotypes were 
associated. This may be attributed to deeper pockets 
in SM compared with NS. Results obtained by Darby, 
et al.34 (2005) and Lee, et al.35 (2012) corroborate 
these results.
One limitation of this study is the absence of 
biochemical validation of the smoking status. Self-
reported smoking status can underestimate true 
smoking prevalence and quantity due to a variety 
of factors such as misunderstanding, intentional 
deception, embarrassment, denial, shame, etc., 
inducing socially desirable responses. Measurement 
of cotinine, a primary metabolite of nicotine, can be 
detected in urine, saliva or serum and could provide 
a reliable biochemical marker of smoking status and 
other tobacco use or exposure over a period of 2 to 
3 days36. 
Conclusion
Within the limitation of the relatively small sample 
size, this study concluded that the most prevalent 
P. gingivalis fimA genotypes detected in periodontal 
participants were genotypes I and II. However, the 
presence of fimA genotype II was higher in SM. 
Periodontal treatment was effective in controlling 
periodontal disease and in reducing P. gingivalis 
fimA type II and V. The authors suggest that more 
longitudinal studies are necessary to establish whether 
genotypes of P. gingivalis fimA can be maintained for 
long periods of time, and whether they influence the 
evolution of periodontal disease over time.
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